HeartSciences shares surge 12.6% premarket after launching MyoVista Insights 1.1 with AI-driven ECG upgrades and improved workflow efficiency.

HeartSciences Inc. (HSCS) surged 12.60% in premarket trading following the commercial launch of MyoVista Insights version 1.1, a major upgrade to its AI-powered ECG management platform. The update enhances usability, expands interoperability across devices, and improves clinical workflow efficiency, with the CEO highlighting strong early adopter validation and ongoing discussions with leading healthcare institutions. The platform’s vendor-agnostic design and AI integration are positioned to reduce operational costs and streamline cardiac care, reinforcing the company’s growth prospects. The significant premarket gain aligns with positive market reception of the product’s potential to drive adoption and long-term revenue growth through enhanced healthcare provider partnerships.